Collector
Dilip Shanghvi-led Sun Pharma's most expensive M&A deal signals fading allure of US generics business | Collector
Dilip Shanghvi-led Sun Pharma's most expensive M&A deal signals fading allure of US generics business
Mint

Dilip Shanghvi-led Sun Pharma's most expensive M&A deal signals fading allure of US generics business

Sun Pharma's $11.75 billion buyout of Organon signifies a strategic shift from focusing on the US generics market to seeking geographic diversification as an antidote to tariff volatility and pricing pressures there. Read how the M&A helps Sun Pharma and why its shares jumped nearly 7% Monday.

Go to News Site